# A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

> **NCT02724228** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 30 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** BMN 111

## Key facts

- **NCT ID:** NCT02724228
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01-26
- **Primary completion:** 2027-12
- **Final completion:** 2028-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724228, "A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02724228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*